advertisement
Abstract #8622 Published in IGR 5-1
Ocular perfusion pressure and visual field index modifications induced by alfa-agonist compound (clonidine 0.125%, apraclonidine 1.0% and brimonidine 0.2%) topical administration: an acute study on primary open-angle glaucoma patients
Costagliola C; Parmeggiani F; Ciancaglini M; D'Oronzo E; Mastropasqua L; Sebastiani AOphthalmologica 2003; 217: 39-44
OBJECTIVE: The aim of this study was to verify the acute effects of alfa-adrenoreceptor agonist eye-drop administration on visual field parameters and ocular perfusion pressure (OPP) in patients affected by primary open-angle glaucoma. METHODS: A prospective, randomized double-blind study was carried out. Sixty-four glaucomatous subjects were enrolled in the clinical trial and subsequently separated into four study groups of 16 patients each, in order to compare the systemic and ocular effects of placebo, clonidine 0.125%, apraclonidine 1.0% and brimonidine 0.2%. RESULTSs: No significant variations in the ocular or systemic parameters were observed after placebo administration. All the alfa-adrenoreceptor agonist compounds induced a significant reduction of intraocular pressure. Clonidine induced significant modifications of mean blood pressure, OPP and visual field indices. The acute administration of apraclonidine did not affect either mean blood pressure or OPP, but nevertheless worsening of the visual field was recorded. The analyzed parameters did not significantly vary after brimonidine instillation. CONCLUSIONS: The present findings demonstrate that the lack of effects on the blood flow and the absence of vasomotor activity at the level of the posterior pole exhibited by brimonidine is related to its alfa-2 selectivity, as appears by comparing this compound with other alpha-agonists available for the management of glaucoma.
Dr. C. Costagliola, Sezione di Clinica Oculistica, Dipartimento di Discipline Medico-Chirurgiche della Comunicazione e del Comportamento, Univ. degli Studi di Ferrara, Corso Giovecca 203, I-44100 Ferrara, Italy. costaciro@libero.it
Classification:
11.3.3 Apraclonidine, brimonidine (Part of: 11 Medical treatment > 11.3 Adrenergic drugs)
